Rapamycin-d3
Cat. No.：YN330059
| 产品名称: | Rapamycin-d3 |
| CAS No.: | 392711-19-2 |
| Chemical Name: | 7-O-demethyl-7-O-(methyl-d3)-rapamycin |
| Synonyms: | Sirolimus-d3; AY-22989-d3 |
| 分子量: | 917.19 |
| 分子式: | C₅₁H₇₆D₃NO₁₃ |
| SMILES: | O=C([C@@]1(O[C@@H](CC[C@H]1C)C[C@@H](/C(C)=C/C=C/C=C/[C@H](C2)C)OC([2H])([2H])[2H])O)C(N3[C@@H](CCCC3)C(O[C@@H](CC([C@@H](/C=C([C@H]([C@H](C([C@@H]2C)=O)OC)O)\C)C)=O)[C@@H](C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)=O)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Rapamycin-d3 (Sirolimus-d3) 是 Rapamycin 的氘代物。Rapamycin 是一种有效且特异性的 mTOR 抑制剂，作用于 HEK293 细胞，抑制 mTOR， IC50为 0.1 nM。Rapamycin 与 FKBP12 结合且抑制 mTORC1。Rapamycin 还是一种自噬 (autophagy) 激活剂，免疫抑制剂。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Kim, Y.C., and Guan, K.-L.mTOR: A pharmacological target for autophagy regulationJ. Clin. Invest.125(1),25-32(2015)
Hosoi, H., Dilling, M.B., Shikata, T., et al.Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cellsCancer Res.59(4),886-894(1999)
Kay, J.E., Kromwel, L., Doe, S.E.A., et al.Inhibition of T and B lymphocyte proliferation by rapamycinImmunology72(4),544-549(1991)
